Oxford Covid-19 vaccine safe for older adults, results show

Remigio Civitarese
Ноября 20, 2020

"We were pleased to see that our vaccine was not only well-tolerated in older adults; it also stimulated similar immune responses to those seen in younger volunteers".

The study's lead author, Andrew Pollard from the University of Oxford also told The Guardian, "Immune responses from vaccines are often lessened in older adults because the immune system gradually deteriorates with age, which also leaves older adults more susceptible to infections".

The new results show that two doses of the vaccine will be needed for each person. Instead, it looked at safety indicators and the body's immune response.

Phase 3 trials of the COV002 study are ongoing to confirm these results, as well as establishing how effective the vaccine is in protecting against Covid-19 disease in a broader group of people, including older adults with underlying health conditions.

"The Phase II interim data for AZD1222 suggests older individuals have lower reactogenicity whilst still maintaining a robust immune response", said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D in a statement. Drugmaker AstraZeneca is working with the university on the vaccine.

"We and it's not a competition with the other developers", Oxford's Professor Pollard said, adding that AstraZeneca would release headline efficacy data before it was published in an academic journal.

West Lafayette resident Mikel Berger said having a vaccine available would be a step in the right direction.

The Philippines' COVID-19 caseload increased to 413,430 on Thursday, with 1,337 additional infections, the Department of Health said.

According to a report by the BBC, two weeks after the volunteers were administered a second dose, more than 99 percent of them had neutralising antibody responses regardless of age. "What we're looking at now are T cells, which are important in identifying and killing cells that are already infected with virus", Ramasamy said. It is also generating a good antibody response.

This month Pfizer/BioNTech and Moderna announced the results of phase 3 trials - which are much larger than phase 2 and normally include tens of thousands of subjects - that suggested both vaccine candidates were effective in preventing COVID-19.

And, crucially, the researchers wanted to know if it might work in older people who are most at risk of severe Covid.

"We will continue to work to ensure that we will have as many vaccines for as many citizens, from as many sources and as fast as possible", he said.

Altre relazioni

Discuti questo articolo

Segui i nostri GIORNALE